Excellent Outcomes for the First Sirolimus Eluting Balloon Tested on Instent Restesosis

Much has been done since studies on conventional balloon angioplasty for BMS instent restenosis showed over 40% new revascularization.  Drug eluting stents, aimed at improving this problem, have never achieved 0% restenosis, which is why technologies such as paclitaxel coated balloons have been developed, with reasonable efficacy (8% to 10% reinterventions rate for BMS restenosis and 17% to 23%<a href="https://solaci.org/en/2017/10/20/excellent-outcomes-for-the-first-sirolimus-eluting-balloon-tested-on-instent-restesosis/" title="Read more" >...</a>

Nuevas estrategias en el territorio femoropoplíteo

New Strategies for the Femoropopliteal Artery

Courtesy of Dr. Carlos Fava. The incidence of peripheral vascular disease is clearly increasing, progressing towards critical ischemic claudication and amputation. Angioplasty is currently the treatment of choice for these pathologies. Several times, an implanted stent ends up cracking due to extensive calcification, increasing the rate of restenosis and worsening critical ischemia.   Technological development on drug-eluting<a href="https://solaci.org/en/2017/10/04/new-strategies-for-the-femoropopliteal-artery/" title="Read more" >...</a>

DEFINE FLAIR and IFR SWEDEHEART: Safety in Revascularization Based on FFR and iFR in Both Stable and ACS Patients

SYNTAX II: Better Stents, IVUS, FFR, or a Combination of All of Them to Catch Up with Surgery

In patients with 3-vessel disease, surgery obtained better outcomes than angioplasty, according to results from the SYNTAX and FREEDOM trials, which used first-generation drug-eluting stents. Even in the BEST trial, which used new-generation stents, surgery still offered far better outcomes. Nobody is surprised by the fact that, whenever angioplasty evolves due to a new device<a href="https://solaci.org/en/2017/09/13/syntax-ii-better-stents-ivus-ffr-or-a-combination-of-all-of-them-to-catch-up-with-surgery/" title="Read more" >...</a>

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

2 Year Outcomes of Lutonix Drug Coated Balloon in Superficial Femoral Arteries

  There are plenty of clinical studies assessing the use of angioplasty for en la peripheral artery disease with restenosis rates as high as 40% and 60% at 6 and 12 months. Drug coated balloons have significantly raised primary patency, but they have mostly been tested in short lesions with mild calcification and no total occlusions.   This<a href="https://solaci.org/en/2017/08/23/2-year-outcomes-of-lutonix-drug-coated-balloon-in-superficial-femoral-arteries/" title="Read more" >...</a>

Diferentes técnicas para mejorar los resultados en claudicación intermitente

Different Techniques for the Improvement of Outcomes in Intermittent Claudication

Peripheral vascular diseases affect over 20% of the population and can affect up to 30% of people with cardiovascular risk factors. The most important treatment points include modification of risk factors, exercise, optimal medical treatment, and timely revascularization.   Given its lower risk of peri-procedural complications (when compared to surgery), endovascular therapy is generally the first<a href="https://solaci.org/en/2017/08/14/different-techniques-for-the-improvement-of-outcomes-in-intermittent-claudication/" title="Read more" >...</a>

CRM vs DES: ¿Cuál se asocia mejor calidad de vida a largo plazo?

MRS vs. DES: Which one is associated with better long-term quality of life?

The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, which included patients with 3-vessel or left main coronary artery lesions, showed that myocardial revascularization surgery (MRS) turned out to be superior to angioplasty with drug-eluting stents (DES), mainly due to differences in acute myocardial infarction and repeat revascularization. Up to this work, patient sensations (which can be<a href="https://solaci.org/en/2017/07/21/mrs-vs-des-which-one-is-associated-with-better-long-term-quality-of-life/" title="Read more" >...</a>

Promising outcomes for DEB in long femoropopliteal artery lesions

Courtesy of Dr. Carlos Fava. For type A and B femoropopliteal artery lesions, percutaneous transluminal angioplasty (PTA) with balloon has proven beneficial; however, drug-eluting balloons (DEB) have shown superiority as regards restenosis.   Some studies have reported favorable outcomes for DEB in type C and D lesions, but its real benefit is still unclear.   This study prospectively<a href="https://solaci.org/en/2017/04/24/promising-outcomes-for-deb-in-long-femoropopliteal-artery-lesions/" title="Read more" >...</a>

angioplastia de la arteria femoral común

A new alternative for PCI of the common femoral artery

Courtesy of Dr. Carlos Fava. Not long ago, atherosclerosis of the common femoral artery used to be treated surgically and, thanks to better training and new balloon devices, we have advanced the endovascular treatment alternative. However, severe calcification continues to be a great limitation.   This study aimed at evaluating the feasibility and one year<a href="https://solaci.org/en/2017/03/07/a-new-alternative-for-pci-of-the-common-femoral-artery/" title="Read more" >...</a>

Dual Antiplatelet Therapy in Men and Women: Are There Differences?

Courtesy of Dr. Agustín Vecchia.   Currently, the duration of dual antiplatelet therapy (DAPT) after stent placement is one of the most highly debated topics in Cardiology. On the one hand, women are usually underrepresented in trials in our specialty; on the other, the fact that symptoms of coronary disease are different in women is well-known.   The aim<a href="https://solaci.org/en/2016/09/12/dual-antiplatelet-therapy-in-men-and-women-are-there-differences/" title="Read more" >...</a>

Xience V: Safe in “Real-Life” Bifurcation Lesions

Courtesy of Dr. Rodrigo Abreu.   INTRODUCTION Bifurcation lesion treatment has evolved considerably in the last years: from balloon angioplasty (with high occlusion and restenosis rates) to bare metal stent angioplasty (with a procedural success around 86% and major adverse cardiac events [MACE] at 1 year around 32%). The subsequent emergence of drug-eluting stents (DES) reduced<a href="https://solaci.org/en/2016/09/09/xience-v-safe-in-real-life-bifurcation-lesions/" title="Read more" >...</a>